| Literature DB >> 21748022 |
Anubhav Thukral1, Manish Mishra, Vaibhava Srivastava, Hemant Kumar, Amit Nandan Dhar Dwivedi, Ram Chandra Shukla, Kamlakar Tripathi.
Abstract
Aims and Objectives. Metabolic dysregulation has failed to explain clinical variability of patients with diabetic nephropathy and hence a renewed interest emerged in haemodynamic factors as determinant of progression and development of diabetic nephropathy. We therefore studied for various factors which can correlate with raised renal vascular resistance in diabetic nephropathy. Material and Methods. Renal vascular resistance was measured in patients with established and incipient diabetic nephropathy and compared with controls using noninvasive color Doppler examinations of intrarenal vasculature. Results. Renal vascular resistance correlated with age, duration of disease, GFR, serum creatinine, and stage of retinopathy. Renal vascular resistance was significantly reduced in patients on treatment with RAAS inhibitors and insulin, than those on OHA and antihypertensives other than RAAS inhibitors. Conclusion. The study implies that renal vascular resistance may help identify diabetics at high risk of developing nephropathy, and these set of patients could be candidates for RAAS inhibition and early insulin therapy even in patients without albuminuria.Entities:
Year: 2011 PMID: 21748022 PMCID: PMC3124948 DOI: 10.1155/2011/656030
Source DB: PubMed Journal: Int J Vasc Med ISSN: 2090-2824
Baseline characteristics of different groups.
| Variable | Diabetic nephropathy (Group A) ( | Diabetics with microalbuminuria (Group B) ( | Diabetics without microalbuminuria (Group C) ( | Nondiabetic controls |
|
|---|---|---|---|---|---|
| Age (yrs) | 58 ± 14.25 | 60 ± 15 | 58.50 ± 15 | 50.00 ± 22.25 | .059 (NS) |
| Sex Ratio (M/F) | 20/11 | 7/7 | 10/2 | 13/6 | .351 (NS) |
| Duration of diabetes (yrs) Median ± IQR | 7.00 ± 11.25 | 3.5 ± 11.75 | 2.5 ± 19.25 | — | .179 (NS) |
| BMI (Kg/m2) | 22.416 ± 4.218 | 22.451 ± 4.007 | 24.008 ± 4.756 | 21.872± 3.974 | .581 (NS) |
| Treatment diabetes (OHA/Insulin) | 21/10 | 9/5 | 9/2 | — | .602 (NS) |
| Treatment hypertension | 9/22 | 8/6 | 0/12 | 1/18 | <.001 |
| Serum Creatinine | 1.9 ± 2.1 | 1.2 ± 1.2 | 1 ± 0.4 | 0.9 ± 0.1 | <.001 |
| GFR (ml/min) | 37.134 ± 23.5 | 48.383 ± 21.042 | 71.456 ± 32.666 | 78.455 ± 18.96 | <.001 |
| FBS (mg/dl) | 170 ± 130.5 | 180 ± 100 | 157 ± 74.5 | 78 ± 15 | <.001* |
| Hb1Ac (%) | 8.5 ± 3.15 | 8.0 ± 2.2 | 7.15 ± 1.55 | 4.1 ± 0.3 | <.001* |
| Cholesterol (mg/dl) | 106 ± 28.5 | 102.5 ± 75 | 73.5 ± 44 | 73 ± 9.75 | <.001** |
| Triglyceride (mg/dl) | 120 ± 126 | 127 ± 153 | 102 ± 97.5 | 88 ± 20 | .144 |
| Mean blood pressure (mmHg) | 96.75 ± 12.1 | 97.95 ± 10.5 | 92.5 ± 10.195 | 97.36 ± 16.16 | .691 (NS) |
| Fundus staging (early/late) Early = stage 1&2 | 19/12 | 8/2* | 3/0* | — | .256 (NS) |
*There was no significant difference between groups A, B, and C.
**There was no significant difference between A and B, but significant difference between A and C, and between B and C.
Comparison of RI and PI between groups.
| Diabetic nephropathy | Diabetics with microalbuminuria | Diabetics without microalbuminuria | Nondiabetic controls |
| |
|---|---|---|---|---|---|
| RI | 0.825 ± 0.178 | 0.742 ± 0.21 | 0.74 ± 0.169 | 0.64 ± 0.097 | <.001 |
|
| |||||
| PI | 1.86 ± 0.82 | 1.388 ± 0.67 | 1.263 ± 0.35 | 1.075 ± 0.39 | <.001 |
Correlation of RI and PI with various variables.
| Index | Parameter | Correlation coefficient |
|
|---|---|---|---|
| RI | Age | 0.329 | .003 |
| PI | Age | 0.383 | .000 |
| RI | BMI | −0.0235 | .840 |
| PI | BMI | 0.0221 | .849 |
| RI | Duration | −0.149 | .266 |
| PI | Duration | 0.0005 | .997 |
| RI | Diastolic blood pressure | −0.002 | .985 |
| PI | Diastolic blood pressure | −0.032 | .78 |
| RI | Systolic blood pressure | 0.0265 | .820 |
| PI | Systolic blood pressure | −0.0188 | .871 |
| RI | Mean blood pressure | 0.001 | .988 |
| PI | Mean blood pressure | −0.0385 | .740 |
| RI | Fasting Blood sugar | −0.145 | .281 |
| PI | Fasting Blood sugar | −0.178 | .183 |
| RI | Cholesterol | −0.162 | .227 |
| PI | Cholesterol | −0.0475 | .725 |
| RI | Triglyceride | −0.143 | .289 |
| PI | Triglyceride | −0.129 | .339 |
| RI | Serum creatinine | 0.368 | .001 |
| PI | Serum creatinine | 0.479 | .000 |
| RI | GFR | −0.456 | .000 |
| PI | GFR | −0.534 | .000 |
| RI | Fundus stage | 0.425 | .001 |
| PI | Fundus stage | 0.525 | .000 |
Comparison of patients with or without raised vascular resistance.
| Characteristics | R.I ≥ 0.8 ( | RI < 0.8 ( |
|
|---|---|---|---|
| Age | 59.467 ± 10.837 | 56.11 ± 8.243 | .198 |
|
| |||
| Sex ratio (M/F) | 19/11 | 18/9 | .988 |
|
| |||
| BMI | 21.458 ± 3.895 | 22.862 ± 6.431 | .179 |
|
| |||
| Duration | 5 ± 9 | 10 ± 19 | .381 |
|
| |||
| Mean B.P. | 95.289 ± 12.508 | 97.11 ± 10.005 | .549 |
|
| |||
| FBS | 160 ± 88 | 170 ± 88.5 | .406 |
|
| |||
| Fundus staging (early/late) | 20/10 | 22/4 | .216 |
|
| |||
| GFR | 42.741 ± 24.043 | 50.79 ± 29.474 | .261 |
|
| |||
| Treatment category (OHA/Insulin) | 26/4 | 14/13 | .010 |
|
| |||
| Treatment hypertension | 8/22 | 11/16 | .399 |
Comparison of patients between treatment groups.
| Characteristics | On insulin*( | On OHA* ( |
|
|---|---|---|---|
| Age | 57 ± 7.508 | 58.25 ± 10.636 | .662 |
|
| |||
| Sex ratio (M/F) | 10/7 | 27/13 | .745 |
|
| |||
| BMI | 23.652 ± 4.014 | 22.381 ± 4.35 | .307 |
|
| |||
| Duration | 10 ± 19.188 | 5 ± 11 | .88 |
|
| |||
| Mean B.P | 96.039 ± 11.699 | 96.2 ± 11.391 | .961 |
|
| |||
| Hb1Ac | 8.3 ± 2.7 | 7.55 ± 2.6 | .341 |
|
| |||
| FBS | 200 ± 117 | 160.5 ± 76.5 | .140 |
|
| |||
| Fundus staging (early/late) | 13/4 | 30/10 | 1 |
|
| |||
| GFR | 51.889 ± 32.596 | 45.725 ± 25.164 | .443 |
|
| |||
| Treatment hypertension | 8/9 | 11/29 | .260 |
|
| |||
| RI | 0.703 ± 0.117 | 0.835 ± 0.182 | .001 |
|
| |||
| PI | 1.33 ± 0.490 | 1.742 ± 0.974 | .094 |
|
| |||
| Proteinuria (mg/day) | 600 ± 2862 | 540.5 ± 648 | .291 |